Dr. Bryan C. Hambley, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 123
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Tulane University School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35125260 -
Hospitalist Physician
MD license D83305
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- West Chester Hospital West Chester, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 123
- Services billed
- 588
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 236 | 46 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 109 | 22 |
| Critical care, first 30-74 minutes | 57 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 33 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 19 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 18 |
| Hospital discharge day management, more than 30 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Cincinnati, OH | 124 |
| Jakafi (ruxolitinib phosphate) | 48 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 38 |
| Pomalyst (pomalidomide) | 37 |
| Dexamethasone Other prescribers in Cincinnati, OH | 26 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Cincinnati, OH | 24 |
| Revlimid (lenalidomide) | 24 |
| Levofloxacin Other prescribers in Cincinnati, OH | 23 |
| Posaconazole | 22 |
| Hydroxyurea Other prescribers in Cincinnati, OH | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $21.19 in total to this clinician.
| Genzyme Corporation | $21.19 |
|---|
| Food and Beverage | $21.19 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $87,204 in research payments for these studies, mostly to the institutions running them.
- M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - Expanded access program FORSNDX-5613IN patients with relapsed/refractory acute leukemias with genetic alterations associated with hoxa overexpression
Syndax Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.